Altium Capital Management LP Esperion Therapeutics, Inc. Transaction History

Altium Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.09 - $8.5 $202,933 - $338,886	-39,869 Reduced 6.04%	620,000 $3.86 Million
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $2.74 Million - $4.09 Million	-503,000 Reduced 43.26%	659,869 $4.42 Million
Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $6.36 Million - $8.9 Million	-1,333,655 Reduced 53.42%	1,162,869 $7.4 Million
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $64,331 - $107,091	-19,261 Reduced 0.77%	2,496,524 $11.6 Million
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $12.1 Million - $30 Million	2,515,785 New	2,515,785 $12.6 Million

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.